Why Harrow stock is back in focus after its latest results Harrow (HROW) has been in the spotlight after Q4 2025 results combined strong revenue growth with an earnings miss, a back end loaded 2026 ...

Harrow (NASDAQ:HROW) executives used the company’s fourth-quarter 2025 earnings call to highlight what CEO Mark Baum ...

Harrow is Monday's IBD Stock Of The Day. The biotech stock is setting up to tack a handle onto a seven-week cup.

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended ...